Therapeutic advances in HBV cure.

Competing Interests: Wai-Kay Seto is on the speakers’ bureau for AstraZeneca. He advises and is on the speakers’ bureau for Abbott. He received grants from Alxion Pharmaceuticals, Boehringer Ingelheim, Pfizer, and Ribo Life Science. He advises, is on the speakers’ bureau for, and received grants from Gilead Sciences. Man-Fung Yuen consults for, advises, is on the speakers’ bureau for, and received grants from Fujirebio Incorporation, Gilead Sciences, Roche, and Sysmex Corporation. He consults for, advises, and received grants from AbbVie, Assembly Biosciences, Arrowhead Pharmaceuticals, and Immunocore. He consults for and advises Abbott Diagnotics, Aligos Therapeutics, AiCuris, Antios Therapeutics, Arbutus Biopharma, Clear B Therapeutics, Dicerna Pharmaceuticals, Finch Therapeutics, GlaxoSmithKline, Janssen, Precision Biosciences, Tune Therapeutics, Vir Biotechnology, and Visirna Therapeutics. He advises and/or received grants from Bristol Myer Squibb, Merck Sharp and Dohme, and Springbank Pharmaceuticals. The remaining authors have no conflicts to report.